Outlook Therapeutics, Inc. Forecast, price target & analysts
Outlook Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Outlook Therapeutics, Inc. Classifications & Recommendation:
Outlook Therapeutics, Inc. Price Target
| Target Price | $8.16 |
| Price | $1.83 |
| Potential |
345.90%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Outlook Therapeutics, Inc. 2026 .
The average Outlook Therapeutics, Inc. target price is $8.16.
This is
345.90%
register free of charge
$22.05
1,104.92%
register free of charge
$1.01
44.81%
register free of charge
|
|
| A rating was issued by 11 analysts: 7 Analysts recommend Outlook Therapeutics, Inc. to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Outlook Therapeutics, Inc. stock has an average upside potential 2026 of
345.90%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 6.85 |
7 Analysts have issued a sales forecast Outlook Therapeutics, Inc. 2025 . The average Outlook Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
7 Outlook Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Outlook Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.94 | -1.82 |
| 16.53% | 53.81% | |
| P/E | negative | |
| EV/Sales | 15.59 |
7 Analysts have issued a Outlook Therapeutics, Inc. forecast for earnings per share. The average Outlook Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Outlook Therapeutics, Inc....
Current Outlook Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 30 2025 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Sep 22 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 28 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 15 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 30 2025 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Sep 22 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 29 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 29 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 28 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 15 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
